Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

por Tanaka, Yoshiya, Fautrel, Bruno, Keystone, Edward C, Ortmann, Robert A, Xie, Li, Zhu, Baojin, Issa, Maher, Patel, Himanshu, Gaich, Carol L, de Bono, Stephanie, Rooney, Terence P, Taylor, Peter C
Publicado 2019

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis

por Genovese, Mark C, Kremer, Joel M, Kartman, Cynthia E, Schlichting, Douglas E, Xie, Li, Carmack, Tara, Pantojas, Carlos, Sanchez Burson, Juan, Tony, Hans-Peter, Macias, William L, Rooney, Terence P, Smolen, Josef S
Publicado 2018

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

por Takeuchi, Tsutomu, Genovese, Mark C, Haraoui, Boulos, Li, Zhanguo, Xie, Li, Klar, Rena, Pinto-Correia, Ana, Otawa, Susan, Lopez-Romero, Pedro, de la Torre, Inmaculada, Macias, William, Rooney, Terence P, Smolen, Josef S
Publicado 2019

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

por Taylor, Peter C., Weinblatt, Michael E., Burmester, Gerd R., Rooney, Terence P., Witt, Sarah, Walls, Chad D., Issa, Maher, Salinas, Claudia A., Saifan, Chadi, Zhang, Xin, Cardoso, Anabela, González‐Gay, Miguel A., Takeuchi, Tsutomu
Publicado 2019

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic d...

por van der Heijde, Desirée, Dougados, Maxime, Chen, Ying-Chou, Greenwald, Maria, Drescher, Edit, Klar, Rena, Xie, Li, de la Torre, Inmaculada, Rooney, Terence P, Witt, Sarah L, Schlichting, Douglas E, de Bono, Stephanie, Emery, Paul
Publicado 2018

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis

por Tanaka, Yoshiya, McInnes, Iain B., Taylor, Peter C., Byers, Nicole L., Chen, Lei, de Bono, Stephanie, Issa, Maher, Macias, William L., Rogai, Veronica, Rooney, Terence P., Schlichting, Douglas E., Zuckerman, Steven H., Emery, Paul
Publicado 2018

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations

por McInnes, Iain B., Byers, Nicole L., Higgs, Richard E., Lee, Jonathan, Macias, William L., Na, Songqing, Ortmann, Robert A., Rocha, Guilherme, Rooney, Terence P., Wehrman, Thomas, Zhang, Xin, Zuckerman, Steven H., Taylor, Peter C.
Publicado 2019

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

por Keystone, Edward C, Taylor, Peter C, Drescher, Edit, Schlichting, Douglas E, Beattie, Scott D, Berclaz, Pierre-Yves, Lee, Chin H, Fidelus-Gort, Rosanne K, Luchi, Monica E, Rooney, Terence P, Macias, William L, Genovese, Mark C
Publicado 2015

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies

por Taylor, Peter C, Kremer, Joel M, Emery, Paul, Zuckerman, Steven H, Ruotolo, Giacomo, Zhong, Jinglin, Chen, Lei, Witt, Sarah, Saifan, Chadi, Kurzawa, Monika, Otvos, James D, Connelly, Margery A, Macias, William L, Schlichting, Douglas E, Rooney, Terence P, de Bono, Stephanie, McInnes, Iain B
Publicado 2018